Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial
R Boada, C Hutaff-Lee, A Schrader, D Weitzenkamp, T A Benke, E J Goldson, A C S Costa, R Boada, C Hutaff-Lee, A Schrader, D Weitzenkamp, T A Benke, E J Goldson, A C S Costa
Abstract
Down syndrome (DS) is the most common genetic cause of intellectual disability. The N-methyl-D-aspartate (NMDA) receptor uncompetitive antagonist, memantine hydrochloride (memantine), has been shown to improve learning/memory and rescue one form of hippocampus synaptic plasticity dysfunction in the best-studied mouse model of DS available, the Ts65Dn mouse. Given the status of memantine as a treatment for Alzheimer's disease (AD) approved by the Food and Drug Administration, the preclinical evidence of potential efficacy in Ts65Dn mice, and the favorable safety profile of memantine, we designed a study to investigate whether the findings in the mouse model could be translated to individuals with DS. In this pilot, proof-of-principle study we hypothesized that memantine therapy would improve test scores of young adults with DS on measures of episodic and spatial memory, which are generally considered to be hippocampus dependent. Accordingly, in this randomized, double-blind, placebo-controlled trial, we compared the effect of 16-week treatment with either memantine or placebo on cognitive and adaptive functions of 40 young adults with DS using a carefully selected set of neuropsychological outcome measures. Safety and tolerability were also monitored. Although no significant differences were observed between the memantine and placebo groups on the two primary outcome measures, we found a significant improvement in the memantine group in one of the secondary measures associated with the primary hypothesis. Only infrequent and mild adverse events were noted.
Figures
References
- Lejeune J, Turpin R, Gautier M. Le mongolism: premier exemple d'aberration autosomique humaine. Ann Genet. 1959;1:1–49.
- Patterson D, Costa AC. Down syndrome and genetics - a case of linked histories. Nat Rev Genet. 2005;6:137–147.
- Parker SE, Mai CT, Canfield MA, Rickard R, Wang Y, Meyer RE, et al. National Birth Defects Prevention Network. Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004–2006. Birth Defects Res A Clin Mol Teratol. 2010;88:1008–1016.
- Pueschel SM, Hopmann MR.Speech and language abilities of children with Down syndrome: a parents's perspectiveIn: Kaiser AP, Gray DB (eds).Enhancing Children's Communication: Research Foundations for Intervention Communication and Language Intervention Seriesvol. 2.P.H. Brookes: Baltimore; 1993335–362.
- Carr J. Stability and change in cognitive ability over the life span: a comparison of populations with and without Down's syndrome. J Intellect Disabil Res. 2005;49:915–928.
- Turner S, Alborz A, Gayle V. Predictors of academic attainments of young people with Down's syndrome. J Intellect Disabil Res. 2008;52:380–392.
- Pennington BF, Moon J, Edgin J, Stedron J, Nadel L. The neuropsychology of Down syndrome: evidence for hippocampal dysfunction. Child Dev. 2003;74:75–93.
- Silverman W. Down syndrome: cognitive phenotype. Ment Retard Dev Disabil Res Rev. 2007;13:228–236.
- Lott IT, Dierssen M. Cognitive deficits and associated neurological complications in individuals with Down's syndrome. Lancet Neurol. 2010;9:623–633.
- Edgin JO, Mason GM, Allman MJ, Capone GT, Deleon I, Maslen C, et al. Development and validation of the Arizona Cognitive Test Battery for Down syndrome. J Neurodev Disord. 2010;2:149–164.
- Edgin JO, Kumar A, Spano G, Nadel L. Neuropsychological effects of second language exposure in Down syndrome. J Intellect Disabil Res. 2011;55:351–356.
- Roizen NJ, Patterson D. Down's syndrome. Lancet. 2003;361:1281–1289.
- Zigman WB, Lott IT. Alzheimer's disease in Down syndrome: neurobiology and risk. Ment Retard Dev Disabil Res Rev. 2007;13:237–246.
- Costa AC. An assessment of the vestibulo-ocular reflex (VOR) in persons with Down syndrome. Exp Brain Res. 2011;214:199–213.
- Costa AC. An assessment of optokinetic nystagmus (OKN) in persons with Down syndrome. Exp Brain Res. 2011;214:381–391.
- Costa AC, Scott-McKean JJ, Stasko MR. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology. 2008;33:1624–1632.
- Lockrow J, Boger H, Bimonte-Nelson H, Granholm AC. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav Brain Res. 2011;221:610–622.
- Rueda N, Llorens-Martin M, Florez J, Valdizan E, Banerjee P, Trejo JL, et al. Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome. J Alzheimers Dis. 2010;21:277–290.
- Scott-McKean JJ, Costa AC. Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine. Learn Mem. 2011;18:774–778.
- McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006. p. CD003154.
- Herrmann N, Li A, Lanctot K. Memantine in dementia: a review of the current evidence. Expert Opin Pharmacother. 2011;12:787–800.
- Lo D, Grossberg GT. Use of memantine for the treatment of dementia. Expert Rev Neurother. 2011;11:1359–1370.
- Hodapp AF, Gerken KC. Correlations between scores for Peabody Picture Vocabulary Test-III and the Wechsler Intelligence Scale for Children-III. Psychol Rep. 1999;84:1139–1142.
- Costa AC. On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome. Dev Neurosci. 2011;33:414–427.
- Rabin LA, Barr WB, Burton LA. Assessment practices of clinical neuropsychologists in the United States and Canada: a survey of INS, NAN, and APA Division 40 members. Arch Clin Neuropsychol. 2005;20:33–65.
- Alexander MP, Stuss DT, Fansabedian N. California Verbal Learning Test: performance by patients with focal frontal and non-frontal lesions. Brain. 2003;126:1493–1503.
- Donders J. A confirmatory factor analysis of the California Verbal Learning Test–Second Edition (CVLT-II) in the standardization sample. Assessment. 2008;15:123–131.
- Reeves CB, Palmer SL, Reddick WE, Merchant TE, Buchanan GM, Gajjar A, et al. Attention and memory functioning among pediatric patients with medulloblastoma. J Pediatr Psychol. 2006;31:272–280.
- Cherney LR, Halper AS. Performance on the California Verbal Learning Test following right hemisphere stroke: a longitudinal study. Top Stroke Rehabil. 2007;14:21–25.
- DeJong J, Donders J. A confirmatory factor analysis of the California Verbal Learning Test–Second Edition (CVLT-II) in a traumatic brain injury sample. Assessment. 2009;16:328–336.
- Lekeu F, Magis D, Marique P, Delbeuck X, Bechet S, Guillaume B, et al. The California Verbal Learning Test and other standard clinical neuropsychological tests to predict conversion from mild memory impairment to dementia. J Clin Exp Neuropsychol. 2010;32:164–173.
- Quigg M, Broshek DK, Barbaro NM, Ward MM, Laxer KD, Yan G, et al. Neuropsychological outcomes after Gamma Knife radiosurgery for mesial temporal lobe epilepsy: a prospective multicenter study. Epilepsia. 2011;52:909–916.
- Mesholam-Gately RI, Giuliano AJ, Zillmer EA, Barakat LP, Kumar A, Gur RC, et al. Verbal learning and memory in older adults with minor and major depression. Arch Clin Neuropsychol. 2012;27:196–207.
- Johnsen GE, Asbjornsen AE. Consistent impaired verbal memory in PTSD: a meta-analysis. J Affect Disord. 2008;111:74–82.
- Albuquerque L, Loureiro C, Martins IP. Effect of lesion site on serial position during list learning: a study with the CVLT. Int J Neurosci. 2008;118:917–933.
- Lund J. Psychiatric aspects of Down's syndrome. Acta Psychiatr Scand. 1988;78:369–374.
- Capone GT, Grados MA, Kaufmann WE, Bernad-Ripoll S, Jewell A. Down syndrome and comorbid autism-spectrum disorder: characterization using the aberrant behavior checklist. Am J Med Genet A. 2005;134:373–380.
- Hanney M, Prasher V, Williams N, Jones EL, Aarsland D, Corbett A, et al. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;379:528–536.
- Costa AC. Alzheimer disease: treatment of Alzheimer disease in Down syndrome. Nat Rev Neurol. 2012;8:182–184.
- Kishnani PS, Heller JH, Spiridigliozzi GA, Lott I, Escobar L, Richardson S, et al. Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10–17. Am J Med Genet A. 2010;152A:3028–3035.
Source: PubMed